No profile data available.
Affimed N.v. (AFMDQ) is a healthcare company in the additional cancer treatment drugs industry, based in Mannheim, Germany, with about 76 full-time employees.
It reported revenue of 8.28 million EUR for fiscal year 2023, down 80.0% from fiscal year 2022, and net income of -105.94 million EUR. In Q3 2024 (the quarter ended September 30, 2024) revenue was 155,000 EUR. Its largest business segment, Collaboration, brought in 94% of segment revenue in fiscal year 2023; USA was the largest region with 100%. Its market capitalization was $4,917 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of October 8, 2026.
, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany.
Affimed reported 8.28 million EUR in revenue for fiscal year 2023, down 80.0% from 41.35 million EUR in fiscal year 2022. In Q3 2024 revenue was 155,000 EUR.
Collaboration, with 7.77 million EUR or 94% of segment revenue in fiscal year 2023. Next: Service (6%).
USA: 100% of revenue by region in fiscal year 2023, followed by Germany (under 1%).
$4,917 as of October 8, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Ocean Biomedical, Inc. (OCEA), Nascent Biotech, Inc. (NBIO), Carisma Therapeutics, Inc. (CARM), Panbela Therapeutics, Inc. (PBLA).